[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diverticulitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diverticulitis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,49,82,106,131,164,188],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100604066","anastomotic-leakage-after-colorectal-surgery-100604066",false,"NCT07144683","Anastomotic Leakage After Colorectal Surgery.","Risk Factors for Anastomotic Leakage After Colorectal Surgery.","AL","Inclusion Criteria:\n\n* Aged ≥18 years\n* Undergoing elective or emergency colorectal resection with primary anastomosis (e.g., ileocolic, colocolic, colorectal, coloanal)\n* Providing written informed consent\n\nExclusion Criteria:\n\n* Colorectal resection without anastomosis (e.g., end stoma)\n* Inflammatory bowel disease (Crohn's, ulcerative colitis)\n* History of previous colorectal surgery involving anastomosis\n* Pregnancy\n* Unable to provide informed consent or comply with follow-up","ALL","18 Years","80 Years",{"count":21,"type":22},430,"ESTIMATED","1 Year","OBSERVATIONAL","Anastomotic leakage (AL) is a severe complication after colorectal surgery, with incidence rates of 2-30%. This prospective, single-center observational cohort study aims to identify and quantify independent risk factors for AL, determine its incidence and impact on outcomes, and develop a predictive model. Approximately 430 patients undergoing colorectal resection with anastomosis will be enrolled from August 2025 to August 2026. Risk factors will be assessed preoperatively, intraoperatively, and postoperatively. AL will be defined and graded per the International Study Group of Rectal Cancer (ISGRC) criteria.",[27,28,29],"Anastomotic Leak","Colorectal Cancer","Diverticulitis",[31,32,33,34,35],"Anastomotic leakage","Colorectal surgery","Risk factors","Postoperative complications","Predictive model","RECRUITING","2026-05-17",{"date":39,"type":40},"2026-05-19","ACTUAL",{"date":42,"type":40},"2025-08-25",{"date":44,"type":22},"2026-09-25",{"name":46,"class":47},"Minia University","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":48},"100637870","diagnosis-of-abdominal-pain-using-rna-levels-the-natural-study-100637870","NCT07579312","Diagnosis of Abdominal Pain Using RNA Levels: The NATURAL Study","Neutrophil Activation Test Using RNA Levels to Assist in the Diagnosis of Abdominal Pain: The NATURAL Study","NATURAL","Inclusion Criteria:\n\nAge \\> 7 yr old Abdominal pain of likely non-traumatic origin Risk of intra-abdominal infection (see IAI signs) Ability to provide informed consent\u002Fassent Potential to order abdominal CT, ultrasound, endoscopy, or surgery for possible IAI\n\nExclusion Criteria:\n\nAny situation where delay could be detrimental Hemodynamically unstable (see age-adjusted criteria) Prisoner or other involuntary detainee Inability to provide informed consent\u002Fassent",true,"7 Years",{"count":60,"type":22},1000,"The NATURAL Study is a prospective, observational, pragmatic study of RNA biomarkers of infections to aid in the diagnosis of abdominal pain.\n\nSummary of Research Study:\n\nHypothesis: A genomic-derived panel of 6 RNA biomarkers present in stabilized whole blood will provide diagnostic information about the presence of bacterial, biofilm, and viral infections in the abdomen. We hypothesize that biomarkers will be more than 90% sensitive with a high (\\>90%) negative predictive value for IAI.\n\nResearch Design: The project design is a prospective, pragmatic, observational study. The NATURAL Study will be sponsored by True Bearing Diagnostics, Inc., and performed at 5 or more academic medical centers. Patients with suspected intra-abdominal infections (IAIs), such as appendicitis, diverticulitis, acute cholecystitis, pancreatitis, peritonitis, pyelonephritis, and abscess are candidates for this study. This is a broad category of patients that are defined by the suspicion of an internal abdominal infection, usually involving some type of advanced imaging analysis, such as CT scan or ultrasound. All participants will be consented for this observational, minimal-risk study prior to venipuncture. Ultimately, The NATURAL Study will determine the positive agreement (\\~sensitivity) and negative agreement (\\~specificity) of the TruNAV RNA biomarkers in relation to the clinical diagnosis of the presence or absence of an IAI, based on CT scans and\u002For surgical confirmation, the current standard of care for diagnosis of IAI.\n\nObjective: To validate a novel RNA fingerprint in ED patients with suspected IAIs.\n\nThe NATURAL Study is designed to determine the accuracy of novel RNA biomarkers for diagnosis of IAI in patients suspected of having IAI. Subgroup analysis will analyse RNA biomarker for multiple types of actual and suspected IAIs (appendicitis, diverticulitis, acute cholecystitis, pancreatitis, peritonitis, pyelonephritis, and abscess.)\n\nSubjects: Approximately 1,000 ED patients presenting with abdominal pain that are candidates to receive CT or other confirmatory diagnostics will be enrolled.",[63,64,65,29,66],"Intra Abdominal Infections","Appendicitis Acute","Pyelonephritis","Epiploic Appendagitis",[63,68,69,65,29,70,71],"Biomarkers","Appendicitis","Epiploic appendagitis","Gastroenteritis","2026-05-06",{"date":74,"type":40},"2026-05-12",{"date":76,"type":40},"2026-04-17",{"date":78,"type":22},"2027-09",{"name":80,"class":81},"True Bearing Diagnostics, Inc.","INDUSTRY",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":91,"conditions":92,"keywords":93,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":48},"100631847","anastomotic-bleeding-in-colorectal-anastomosis-relating-to-the-placement-of-the-stapler-spike-to-the-staple-line-100631847","NCT07506005","Anastomotic Bleeding in Colorectal Anastomosis Relating to the Placement of the Stapler Spike to the Staple Line","Anastomotic Bleeding in Primary Double-stapled Colorectal Anastomosis Relating to the Placement of the Stapler Spike to the Staple Line","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Colorectal surgery with primary colorectal anastomosis using the double-stapling technique, including side-to-end or end-to-end anastomosis\n* Documented anastomotic orientation (mesenteric vs. antimesenteric)\n\nExclusion Criteria:\n\n* TME",{"count":90,"type":22},102,"Each colorectal anastomosis is routinely evaluated intraoperatively by sigmoidoscopy and, in the presence of signs of bleeding, also postoperatively (persistent rectal bleeding within 24 hours after surgery).",[28,29],[94,95,96],"Colorectal anastomosis","Double Stapling","Anastomotic Bleeding","2026-03-29",{"date":99,"type":40},"2026-04-01",{"date":101,"type":40},"2024-12-18",{"date":103,"type":22},"2028-12-31",{"name":105,"class":47},"Kepler University Hospital",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":113,"targetDuration":115,"studyType":24,"phases":4,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":129,"locationsCount":48},"100595019","prospective-observational-analysis-of-circulating-endocan-levels-in-patients-presenting-with-acute-diverticulitis-100595019","NCT07027007","Prospective Observational Analysis of Circulating Endocan Levels in Patients Presenting With Acute Diverticulitis","DIVENDO","Inclusion Criteria:\n\n* Patients who have signed informed consent\n* Patients who are affected by acute diverticulitis after clinical evaluation and imaging (i.e. u.s. or CeCT)\n\nExclusion Criteria:\n\n* Immunosuppressed patients\n* Patients suffering chronic inflammatory diseases\n* Patients with concomitant malignancy, cardiac, renal and haepatic failure\n* History of major vascular surgery (aneurysmectomy)\n* Pregnant women\n* Patients participating in other studies that may interfere with the outcome of the intervention.",{"count":114,"type":22},60,"12 Months","Quantify the level of endocan in blood samples collected from patients with acute diverticulitis in the emergency department. Determine if endocan levels are correlated with the severity of diverticulitis according to the WSES classification. Assess whether patients requiring emergency surgical intervention have higher endocan values compared to others.",[29],[119,120,121],"endocan","acute diverticolitis","diverticulitis classification","NOT_YET_RECRUITING","2025-06-10",{"date":125,"type":40},"2025-06-18",{"date":127,"type":22},"2025-09-30",{"date":78,"type":22},{"name":130,"class":47},"IRCCS Ospedale San Raffaele",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":141,"phases":142,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":48},"100568911","phase-2-clinical-trial-with-mbk-01-intestinal-microbiota-capsules-for-the-treatment-of-patients-with-recurrent-diverticulitis-100568911","NCT06687382","Clinical Trial With MBK-01, Intestinal Microbiota Capsules, for the Treatment of Patients With Recurrent Diverticulitis","A Phase IIa Randomized, Controlled, Open-label Clinical Trial to Assess the Efficacy, Safety, and Tolerability of the Investigational Medicinal Product MBK-01, FSPIM (Full Spectrum & Purified Intestinal Microbiota) Oral Capsules, as Well as to Determine the Optimal Dosage in the Treatment of Patients With Recurrent Diverticulitis (DIREBIOT)","Inclusion Criteria:\n\n* Patients of both sexes aged 18-70 (both included).\n* Three or more episodes compatible with a diagnosis of acute diverticulitis of the left or sigmoid colon in the 3 years prior to signing the informed consent. The diagnosis of each episode of diverticulitis must have been made by demonstrating inflammation in the colon compatible with diverticulitis in an imaging test (computed tomography or ultrasound) and presenting at least one of the following analytical or clinical alterations :abdominal pain, vomiting, intestinal obstruction, body temperature over 38ºC, constipation (less than one bowel movement every 3 days), elevated acute-phase reactants (leukocytes higher than 11,000 cells\u002FµL and\u002For C-reactive protein (CRP) higher than 5mg\u002FdL and\u002For procalcitonin higher than 0.2), rectal bleeding.\n* Not having had any symptomatic episode of acute diverticulitis in the 30 days prior to signing the informed consent.\n* In the case of women and men of reproductive age, for safety, those who agree to follow the required contraceptive measure from the signing of the informed consent until the penultimate visit of the follow-up period.\n* Patients who have signed the informed consent, either autonomously or through a legal representative.\n\nExclusion Criteria:\n\n* Patients for who the information on episodes of acute diverticulitis required for inclusion in the study cannot be fully verified.\n* Patients with acute diverticulitis in the ascending colon, transverse colon or other locations other than the descending or sigmoid colon.\n* Previous colonic resection of any segment of the colon.\n* Medical history of colorectal cancer.\n* Having taken a mechanical colonic preparation in the 3 months prior to signing the informed consent.\n* History of abdominal surgery.\n* Allergy or intolerance to any component of the investigational medicinal product or ancillary medicinal products (amoxicillin, clavulanic acid, fosfomycin or metronidazole) used in the trial.\n* Prior administration of fecal microbiota transplantation (FMT).\n* Systemic antibiotic treatment in the 30 days prior to signing the informed consent.\n* Taking a marketed probiotic\u002Fprebiotic\u002Fsymbiotic in the 30 days prior to signing the informed consent.\n* Treatment with rifaximin or mesalazine in the 30 days prior to signing the informed consent.\n* Presence of hereditary or acquired immunodeficiency.\n* Chronic infectious diseases such as hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV).\n* Pregnancy or lactation.\n* Any other condition that, in the opinion of the investigator, could prevent or hinder compliance with the study.","70 Years",{"count":140,"type":22},81,"INTERVENTIONAL",[143],"PHASE2","Patients with diverticulitis experience a prolonged course of the disease and report a variety of physical, psychological and social symptoms, which highly impacts in their quality of life. Although antibiotic therapy has been the preferred treatment option for acute diverticulitis, it does not control the disease in 40 percent of the patients with complicated diverticulitis and 13 to 23 percent of the patients with non-complicated diverticulitis, which results in chronic and recurrent episodes of diverticulitis. As the episodes repeat, the outpatient conservative treatment has worse success rates and the incidence of complicated diverticulitis with abscess increases up to five times.\n\nTherefore, it is of great importance to establish new treatments in order to avoid the recurrences of the disease. As of today, there is not enough evidence of the efficacy of current treatment options to prevent recurrences in patients with diverticulitis, but recent approaches suggest the modification of intestinal microbiota as a preventive strategy.\n\nMicrobial imbalance (dysbiosis) has been proposed as a mechanism involved in the transition from diverticulosis to diverticulitis, inflammation and some of the symptoms of the disease. In this way, fecal microbiota transplantation (FMT) could have an important role in the prevention of new episodes, as it can modify the composition of the intestinal microbiota in a less invasive and more physiological way. Until now the efficacy of FMT in patients with recurrent diverticulitis has not been assessed; however, its benefits and safety have been demonstrated in studies for inflammatory bowel disease (IBD), a pathology with similarities to diverticulitis in its symptoms and underlying inflammation.\n\nThe objective of the present clinical trial is to assess the efficacy of MBK-01 (heterologous lyophilized intestinal microbiota oral capsules) in reducing the frequency of episodes in recurrent diverticulitis, its safety and tolerability and to determine the optimal dosing regimen.",[29,146],"Diverticulitis of Sigmoid",[148,149,150,151,152,153,154],"Recurrent Diverticulitis","Diverticular Disease","Acute Diverticulitis","Diverticulosis","Fecal Microbiota Transplantation","Fecal Microbiota Transfer","Intestinal Microbiota","2025-06-04",{"date":157,"type":40},"2025-06-05",{"date":159,"type":40},"2025-04-03",{"date":161,"type":22},"2027-04",{"name":163,"class":81},"Mikrobiomik Healthcare Company S.L.",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":173,"conditions":174,"keywords":176,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":48},"100536501","comparison-of-nom-for-acld-between-medical-and-surgical-ward-100536501","NCT06265649","Comparison of NOM for ACLD Between Medical and Surgical Ward","Acute Left Colon Diverticulitis: is it Still a Surgical Disease When Only Medical Treatment is Required? A Retrospective Study Based on Propensity Score Matching","Inclusion Criteria:\n\n* patients affected by ALCD using a contrast-enhanced CT scan at admission undergoing NOM\n\nExclusion Criteria:\n\n* immediate indication for surgery (i.e. patients with Hinchey III or IV ALCD or septic patients with Hinchey II)",{"count":172,"type":22},175,"In Europe, patients with acute left colon diverticulitis (ALCD) are usually admitted to surgical wards even when only medical treatment is required. The study compares ALCD non-operative management (NOM) between surgical and non-surgical environments regarding clinical outcomes, hospitalization length(LOS), and follow-up.",[29,175,150],"Colon Disease",[177,178],"diverticulitis","non-operative management","2025-04-02",{"date":181,"type":40},"2025-04-04",{"date":183,"type":40},"2024-01-01",{"date":185,"type":22},"2026-01",{"name":187,"class":47},"Ospedali Riuniti Trieste",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":198,"conditions":199,"keywords":201,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":48},"100502983","robotic-versus-laparoscopic-colectomy-for-diverticulitis-100502983","NCT05829343","RObotic Versus LAparoscopic Colectomy for DIverticulitis.","RObotic vs LAparoscopic Colectomy for DIverticulitis. A Multicenter Observational Prospective Study.","ROLADI","Inclusion Criteria:\n\n* Age \\> 18 years\n* Elective or delayed urgency colorectal resection for left-sided DD\n* Fully minimally invasive (robotic or laparoscopic) procedures.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Urgent resection for DD\n* Hybrid minimally invasive resection\n* Conventional open resection.",{"count":197,"type":22},1450,"Over the last decade there has been a growing interest toward the application of robotic approach for diverticular disease. The evidence available on the literature showed that robotic approach, compared to the laparoscopic surgery, offers significant advantages in terms of conversion rate and shortened hospital stay for the treatment of diverticular disease.\n\nThe investigators aimed at evaluating whether robotic colectomy may offer some advantages over the laparoscopic approach for surgical treatment of diverticular disease by analyzing a one year multicenter prospective study.\n\nPrimary objective is to evaluate if robotic approach reduce the rate of conversion to open approach compared to laparoscopic surgery. Secondary objective is to assess difference between the two approaches in terms of rate of intraoperative complication, postoperative morbidities (according with Clavien and Dindo Classification), hospital stay and at one year follow up. Inclusion criteria are: elective colectomy for complicated or non-complicated diverticular disease performed with laparoscopic or robotic approach and age between 18 and 90 years. Exclusion criteria are non-elective colectomy (emergency resection), open procedure, diverticular resection performed during other procedure (i.e. colectomy for cancer). Data will be collected in one year from the start of the study.\n\nDue to the lack of available evidence, it is impossible to draw definitive conclusions. With this study, the investigators hope to clarify the role of the robotic approach in the treatment of diverticular disease.",[200,29],"Diverticular Diseases",[149,202,203,204,32],"Robotic surgery","Laparoscopic surgery","Minimal invasive surgery","2025-01-26",{"date":207,"type":40},"2025-01-29",{"date":209,"type":40},"2023-06-01",{"date":211,"type":22},"2025-06-30",{"name":213,"class":47},"S.M. Misericordia Hospital"]